Skip to main content

FDA-Cleared TreatmentsCovered by Most InsurancePhysician-Led Care

Can SPRAVATO Help When Depression Comes With Suicidal Thoughts?

SPRAVATO is FDA-approved for major depressive disorder with acute suicidal thoughts or actions in adults, taken with an oral antidepressant, and is given in a certified setting with monitoring. It is one part of a plan, never the whole plan. Evaluations are available in person or by video across Colorado, with benefits verified first.

Watch: SPRAVATO and Suicidal Thoughts: The Second Approved Indication Explained

SPRAVATO and Suicidal Thoughts: The Second Approved Indication Explained

From the TMS Therapy Centers Colorado video series. Educational only; not medical advice.

When depression comes with suicidal thoughts, the question of how quickly a treatment can begin to help stops being academic. This article explains what the second FDA approval for SPRAVATO covers, what it does not claim, and what a plan generally includes. It comes from TMS Therapy Centers Colorado, a physician-led psychiatric clinic serving the Denver metro and all of Colorado.

If you are in crisis, call or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency room.

Immediate danger comes first

The 988 Suicide and Crisis Lifeline is available by call or text at any hour. Where there is immediate danger, an emergency room is the right place. Our article on when depression becomes an emergency describes the signs that call for emergency care and the wide middle ground that calls for prompt evaluation.

A less widely known approval

For people who are safe but struggling, SPRAVATO holds a second FDA approval that is less widely known than the first. It covers major depressive disorder with acute suicidal thoughts or actions in adults, taken together with an oral antidepressant. The first approval is for treatment-resistant depression in adults. You can read the basics on our SPRAVATO page.

Why the approval exists: timing

The reason this approval exists comes down to timing. Standard antidepressants usually need several weeks before mood begins to shift, and those weeks can feel unbearably long.

Esketamine works on the glutamate system rather than serotonin. In the studies that supported this approval, improvement in depressive symptoms was measured within the first day after dosing in some participants, alongside the oral antidepressant that was started at the same time. Results varied, and not everyone improved.

What the approval does not claim

The approval covers rapid reduction of depressive symptoms in this group. It does not claim to prevent suicide. The people in those studies were also receiving hospital-level care.

That context matters. SPRAVATO is not a stand-alone answer to suicidal thinking, and it would be a mistake to present it as one. It is one component of a broader plan.

What a plan generally includes

SPRAVATO is one part of a plan in this situation, never the whole plan. A plan generally includes:

  • A thorough psychiatric evaluation
  • A safety assessment
  • A clear arrangement for support between appointments
  • An oral antidepressant
  • Sometimes therapy or a higher level of care

The psychiatrist decides what fits. The plan is individualized, revisited often, and adjusted as the situation changes.

Why the structure suits this situation

The supervised, monitored structure of SPRAVATO sessions is well suited to someone who benefits from regular contact with a clinical team during a hard stretch. Sessions take place in a certified setting, with observation after the spray. Staff see the person regularly, which makes it easier to notice change.

Family members often find it reassuring that each session includes a check-in before the spray and observation afterward. Knowing that a clinical team is paying close attention can ease some of the weight families carry.

What an evaluation covers

An evaluation in this situation is thorough. A psychiatrist asks directly about suicidal thoughts, because the answer shapes how closely someone is followed and which treatments are considered. It also reviews current and past medications, medical history, and what supports exist at home. Blood pressure and other medical factors are checked, since esketamine can raise blood pressure temporarily. A short questionnaire such as the PHQ-9 depression test can help describe symptoms beforehand, though it does not replace emergency help.

Why safety assessment is part of every step

A safety assessment is not a one-time event. It is repeated through the course so that any change in thoughts, mood, or circumstances is noticed early. The clinical team asks how things have been since the last session, and family members who are involved can share what they have seen. This ongoing attention is part of why a monitored, supervised treatment may suit someone during a difficult period. It is also why the plan is never limited to the spray itself.

Other treatment options

SPRAVATO is not the only option, and it may not be the right one for everyone. Other approaches include psychotherapy, medication, and transcranial magnetic stimulation, which is FDA-cleared for major depressive disorder. A psychiatrist considers what fits the person's situation, safety, and preferences.

For families and friends

If someone you love is struggling with thoughts of suicide, a few steps help:

  • Ask directly. Asking does not plant the idea.
  • Listen without trying to fix.
  • Keep 988 handy, and use it for yourself too if you need support.
  • Encourage an evaluation and offer to help with the first step.
  • Seek emergency care if there is immediate danger.

Starting the conversation

An evaluation can begin by private video from anywhere in Colorado, which can make the first step easier for someone who is struggling to leave home. The sessions themselves take place in person in a certified setting.

How care works at TMS Therapy Centers Colorado

TMS Therapy Centers Colorado was founded by William Kromka, MD, a board-certified psychiatrist. SPRAVATO is given in person in a certified setting, with the evaluation available in person or by private video anywhere in Colorado. No referral is needed, and most major insurance plans are accepted, with benefits verified and prior authorization handled before treatment begins. To begin, call 720-500-7873.

SPRAVATO is FDA-approved for major depressive disorder with acute suicidal thoughts or actions in adults, taken together with an oral antidepressant. The approval covers rapid reduction of depressive symptoms in this group. It does not claim to prevent suicide, and it is one part of a broader plan.